Alumis Inc

This study tested a new daily medicine called ESK-001 in 862 adults with moderate to severe plaque psoriasis. The goal was to see if it reduces psoriasis severity and is safe, comparing it to a placebo and an existing drug (apremilast). Participants took the medicine for 24 weeks…

This study tested whether a new daily pill, ESK-001, can safely reduce psoriasis severity in adults with moderate to severe plaque psoriasis. Over 900 participants took either ESK-001, a placebo (dummy pill), or an approved psoriasis drug (apremilast) for 24 weeks. Researchers me…

This study looked at how the body processes a drug called ESK001 in people with different levels of liver function. Researchers gave a single dose to 32 adults, including healthy volunteers and those with mild, moderate, or severe liver impairment. The goal was to measure drug le…

This early-phase study tested the safety and how the body processes a new drug called A-005 in 135 healthy adults. Participants received either single or multiple doses of A-005 or a placebo. The goal was to check for side effects and measure drug levels in the blood and spinal f…

This study looked at how a new drug called ESK-001 affects the heart's rhythm in 52 healthy adults aged 18 to 55. Participants received ESK-001, a placebo (fake drug), and moxifloxacin (a drug known to affect heart rhythm) at different times. The main goal was to see if ESK-001 c…

This completed phase 1 study looked at how different levels of kidney function affect the way the body processes a single dose of ESK-001, an experimental drug. Sixteen participants with healthy kidneys or mild, moderate, or severe kidney impairment each took one oral dose. Resea…